Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment
Aaron F. Carlin, Alex E. Clark, Antoine Chaillon, Aaron F. Garretson, William Bray, Magali Porrachia, AsherLev T Santos, Tariq M. Rana, Davey M. Smith
Abstract
We isolated a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.2 variant from a person with coronavirus disease 2019 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing were performed with both parental SARS-CoV-2 and multiple variants of concern. We found that neither nirmatrelvir resistance nor absence of neutralizing immunity was a likely cause of the recrudescence.
Topics & Concepts
MedicineVirologyImmunologyCoronavirusRitonavirSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Antibody2019-20 coronavirus outbreakDiseaseVirusInfectious disease (medical specialty)Viral loadInternal medicineAntiretroviral therapyOutbreakSARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesCOVID-19 Clinical Research Studies